odanacatib   Click here for help

GtoPdb Ligand ID: 6478

Synonyms: MK-0822
Compound class: Synthetic organic
Comment: Odanacatib, a cathepsin K inhibitor, has clinically shown prevention of bone loss in osteoporosis. However, in Sept 2016 Merck ceased development because of an increased risk of stroke in the Phase 3 results (see the In the Pipeline commentary)
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 107.44
Molecular weight 525.17
XLogP 5.26
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES N#CC1(CC1)NC(=O)C(CC(F)(C)C)NC(C(F)(F)F)c1ccc(cc1)c1ccc(cc1)S(=O)(=O)C
Isomeric SMILES N#CC1(CC1)NC(=O)[C@H](CC(F)(C)C)N[C@H](C(F)(F)F)c1ccc(cc1)c1ccc(cc1)S(=O)(=O)C
InChI InChI=1S/C25H27F4N3O3S/c1-23(2,26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27,28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3,34)35/h4-11,20-21,31H,12-14H2,1-3H3,(H,32,33)/t20-,21-/m0/s1
1. Brixen K, Chapurlat R, Cheung AM, Keaveny TM, Fuerst T, Engelke K, Recker R, Dardzinski B, Verbruggen N, Ather S et al.. (2013)
Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
J Clin Endocrinol Metab, 98 (2): 571-80. [PMID:23337728]
2. Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong le T, Falgueyret JP, Kimmel DB, Lamontagne S, Léger S, LeRiche T et al.. (2008)
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
Bioorg Med Chem Lett, 18 (3): 923-8. [PMID:18226527]